Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 1/20 | 0.62 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.62 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.62 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.62 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.62 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.62 |
| ▸ | RXRA | P19793 | 5/20 | 0.54 |
| ▸ | RXRB | P28702 | 5/20 | 0.54 |
| ▸ | RXRG | P48443 | 5/20 | 0.54 |
| ▸ | PPARD | Q03181 | 1/20 | 0.52 |
| ▸ | PTGDR2 | Q9Y5Y4 | 11/20 | 0.49 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1202205 | 0.92 | PSEN1 (0.63) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1202458 | 0.88 | PSEN1 (0.46) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL15858242 | 0.87 | PTGDR2 (0.47) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL12891257 | 0.84 | APP (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL13745205 | 0.79 | PTGDR2 (0.59) | PTGDR2 | |
| SCHEMBL1202743 | 0.78 | APP (0.58) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1202156 | 0.78 | APP (0.46) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3565115 | 0.78 | RXRA (0.55) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4597643 | 0.78 | PSEN1 (0.59) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1203311 | 0.78 | APP (0.54) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140187786-A1 | 1,3,4-TRISUBSTITUTED BENZENES | ENVIVO PHARMACEUTICALS, INC. (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140187786-A1 | 1,3,4-TRISUBSTITUTED BENZENES | ENVIVO PHARMACEUTICALS, INC. (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140187786-A1 | 1,3,4-TRISUBSTITUTED BENZENES | ENVIVO PHARMACEUTICALS, INC. (US) | 2014-07-03 | — | — | US | disclosed |
| US-20110040094-A1 | 1,3,4-TRISUBSTITUTED BENZENES | ENVIVO PHARMACEUTICALS, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| US-20110040094-A1 | 1,3,4-TRISUBSTITUTED BENZENES | ENVIVO PHARMACEUTICALS, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| US-20110040094-A1 | 1,3,4-TRISUBSTITUTED BENZENES | ENVIVO PHARMACEUTICALS, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| WO-2009036428-A2 | 1,3,4-TRISUBSTITUTED BENZENES | ENVIVO PHARMACEUTICALS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| WO-2009036428-A2 | 1,3,4-TRISUBSTITUTED BENZENES | ENVIVO PHARMACEUTICALS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110040094-A1 | 1,3,4-TRISUBSTITUTED BENZENES | BACE1, BACE2, PSEN1 | PSEN1 3/4885PSEN2 5/4885APH1B 6/4885 |
| US-20140187786-A1 | 1,3,4-TRISUBSTITUTED BENZENES | BACE1, BACE2, PSEN1 | PSEN1 3/4885PSEN2 5/4885APH1B 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.